Citations

Clear

426 citation(s) found for "ST, Reza".

Activation of Aryl Hydrocarbon Receptor Inhibits Airway Smooth Muscle Proliferation
Reza, M.I., Balraj, Premanand , Ramakrishnan, Y. , Pabelick, C.M., Britt, Rodney D. , Pabelick, C.M., Prakash, Y. S. , Sathish, Venkatachalem

Mayo Clinic

A70. RELAX ALREADY! MECHANISTIC INSIGHTS INTO AIRWAY SMOOTH MUSCLE BIOLOGY | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A2326-A2326

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2326 Get It

Transcatheter Aortic Valve Replacement Prognostication with Augmented Mean Arterial Pressure
Agasthi, Pradyumna , Seri, Amith Reddy , Barry, Timothy , Shanbhag, Anusha , Wang, Yuxiang , Eleid, Mackram F. , Fortuin, David, Sweeney, John P., Pollak, Peter , Sabbagh, Abdallah El , Lester, Steven J., Freeman, William K., Naqvi, Tasneem Z. , Holmes, David R. , Appleton, Christopher P., Arsanjani, Reza , Seri, Amith R, Barry, Timothy , Arsanjani, Reza , Chao, Chieh‐Ju

Mayo Clinic

Journal of Cardiovascular Development and Disease | April 26, 2023 | Volume: 10 | Issue: 5 | Pages: 192

10.3390/jcdd10050192 | PMID 37233159 Get It

Background: Post-transcatheter aortic valve replacement (TAVR) patient outcome is an important research topic. To accurately assess post-TAVR mortality, we examined a family of new echo parameters (augmented systolic blood pressure (AugSBP) and arterial mean pressure (AugMAP)) derived from blood pressure and aortic valve gradients. Methods: Patients in the Mayo Clinic National Cardiovascular Diseases Registry-TAVR database who underwent TAVR between 1 January 2012 and 30 June 2017 were identified to retrieve baseline clinical, echocardiographic and mortality data. AugSBP, AugMAP and valvulo-arterial impedance (Zva) (Zva) were evaluated using Cox regression. Receiver operating characteristic curve analysis and the c-index were used to assess the model performance against the Society of Thoracic Surgeons (STS) risk score. Results: The final cohort contained 974 patients with a mean age of 81.4 ± 8.3 years old, and 56.6% were male. The mean STS risk score was 8.2 ± 5.2. The median follow-up duration was 354 days, and the one-year all-cause mortality rate was 14.2%. Both univariate and multivariate Cox regression showed that AugSBP and AugMAP parameters were independent predictors for intermediate-term post-TAVR mortality (all p < 0.0001). AugMAP1 < 102.5 mmHg was associated with a 3-fold-increased risk of all-cause mortality 1-year post-TAVR (hazard ratio 3.0, 95%confidence interval 2.0–4.5, p < 0.0001). A univariate model of AugMAP1 surpassed the STS score model in predicting intermediate-term post-TAVR mortality (area under the curve: 0.700 vs. 0.587, p = 0.005; c-index: 0.681 vs. 0.585, p = 0.001). Conclusions: Augmented mean arterial pressure provides clinicians with a simple but effective approach to quickly identify patients at risk and potentially improve post-TAVR prognosis.
Evaluation of the Educational Value of Low-Cost Training Model for Emergency Cricothyrotomy
Nour, Mohammad Ghasemi , Sadrzadeh, Sayyed Majid , Assadi, Reza , AlJamal, Yazan N, Assadi, Reza , Moradi, Elnaz Vafadar , AlJamal, Yazan , Arghami, Arman

Mayo Clinic

Surgical Innovation | March 31, 2023 | Volume: 30 | Issue: 3 | Pages: 383-389

10.1177/15533506231162992 | PMID 37002547 Get It

Background In this study, we aimed to evaluate the educational value and students’ satisfaction with the hand-made low-cost cricothyrotomy simulation model. Materials and Methods A low-cost and hand-made model and a high-fidelity model were used to assess the students. The students’ knowledge and satisfaction were evaluated using a 10-item checklist and a satisfaction questionnaire, respectively. Medical interns in the present study participated in a two-hour briefing and debriefing session held in the Clinical Skills Training Center by an emergency attending doctor. Results Based on the results of data analysis, no significant differences were found between the two groups in terms of gender, age, the month of internship, and last semester’s grade ( P = .628, .356, .847, and .421, respectively). We also found no significant differences between our groups in terms of the median score of each item in the assessment checklist ( P = .838, .736, .805, .172, .439, .823, .243, .950, .812, and .756, respectively). The study groups had no significant difference in the median total scores of the checklist as well ( P = .504). Regarding the students’ satisfaction, our results showed that interns evaluated their experience of the model as positive (median scores of 4 and 5 out of 5). They also gave the hand-made model a median score of 7 in comparison with the high-fidelity model and 8 out of 10 for its usability. Conclusion The study results showed that a low-cost model could be as effective as an expensive high-fidelity model for teaching the necessary knowledge of cricothyrotomy techniques to medical trainees.
Characterizing changes in tumor mutational burden (TMB) by serial circulating tumor DNA (ctDNA) testing in patients with advanced prostate cancer (aPC).
Kwon, Eugene D., Mahmoud, Ahmed , Pessoa, Rodrigo Rodrigues , Drusbosky, Leylah , Mahmoud, Ahmed M , Childs, Daniel S. , Ahmed, Mohamed E. , Nabavizadeh, Reza , Tsai, Jill , Bucheit, Leslie

Mayo Clinic

Journal of Clinical Oncology | March 14, 2023 | Volume: 41 | Issue: 6_suppl | Pages: 239-239

10.1200/jco.2023.41.6_suppl.239 Get It

239 Background: In part, TMB guides therapeutic decisions on the use of immune checkpoint inhibitors (ICIs) in aPC. Most patients (pts) with aPC do not have high TMB (TMB-H) at the time of initial assessment. However, TMB changes over time (from treatment pressure) as pts progress through lines of therapy (LOT) has not been extensively explored in aPC. We describe real world data on changes to blood TMB (bTMB) in pts with aPC exposed to several LOT. Methods: Genomic results from pts with aPC who had ≥1 ctDNA test(s) with TMB analyzed (Guardant360, Guardant Health, Inc) as part of clinical care from Oct 2020 – Jun 2022 were retrospectively queried. Clinical factors were extracted from test requisition forms; pts from Mayo Clinic had additional factors, including intervening treatment, extracted from medical records. High bTMB (TMB-H) was defined as ≥13.4 mut/Mb, as previously reported. Proportions were compared using Fisher’s Exact Test. Results: 316 patients with a median age of 72 (range: 44-91) were analyzed. Initial median TMB for the entire cohort was 8.18 mut/Mb (range: 0.01-268.3). On subsequent test, TMB decreased in 122(40%), increased in 173(55%), of whom 29 (17%) became TMB-H; 21 (7%) had unchanged TMB. Median time between tests was 182 days (range: 21-578). 101 patients with 262 tests and a median age of 71 years (range: 46-87) were clinically annotated in the Mayo cohort of whom 58 had >2 consecutive TMB scores: 25 (43%) had TMB increase, of whom 4 (16%) became TMB-H, 23 (40%) had TMB decrease, 10 (17%) had dynamic changes with increases and decreases. Numeric but not statistically significant differences in clinical factors were observed between groups (p>0.05). Conclusions: In this real world cohort, variation in TMB is seen with increasing LOT. Importantly, nearly 1 in 5 patients with increasing tumor mutational burden develop TMB-H, which may be a clinically actionable finding as these pts become eligible for ICI. Findings underscore the importance of repeat genetic testing with time and LOT. [Table: see text]
Next-Generation Hydrogels as Biomaterials for Biomedical Applications: Exploring the Role of Curcumin
Vazifehdoost, Maryam, Alhashemi, Samira Hossaini , Davoudi, Hesam, Dehshahri, Ali , Fekri, Hojjat Samareh, Madamsetty, Vijay Sagar , Dehshahri, Ali , Thakur, Vijay Kumar , Zarrabi, Ali , Mohammadinejad, Reza

Mayo Clinic

ACS Omega | February 28, 2023 | Volume: 8 | Issue: 10 | Pages: 8960-8976

10.1021/acsomega.2c07062 | PMID 36936324 Get It

The Role of Artificial Intelligence in Echocardiography
Barry, Timothy , Farina, Juan M. , Ayoub, Chadi , Jeong, Jiwoong , Patel, Bhavik N. , Banerjee, Imon , Arsanjani, Reza , Farina, Juan M , Arsanjani, Reza , Banerjee, Imon , Chao, Chieh‐Ju

Mayo Clinic

Journal of Imaging | February 20, 2023 | Volume: 9 | Issue: 2 | Pages: 50

10.3390/jimaging9020050 | PMID 36826969 Get It

Echocardiography is an integral part of the diagnosis and management of cardiovascular disease. The use and application of artificial intelligence (AI) is a rapidly expanding field in medicine to improve consistency and reduce interobserver variability. AI can be successfully applied to echocardiography in addressing variance during image acquisition and interpretation. Furthermore, AI and machine learning can aid in the diagnosis and management of cardiovascular disease. In the realm of echocardiography, accurate interpretation is largely dependent on the subjective knowledge of the operator. Echocardiography is burdened by the high dependence on the level of experience of the operator, to a greater extent than other imaging modalities like computed tomography, nuclear imaging, and magnetic resonance imaging. AI technologies offer new opportunities for echocardiography to produce accurate, automated, and more consistent interpretations. This review discusses machine learning as a subfield within AI in relation to image interpretation and how machine learning can improve the diagnostic performance of echocardiography. This review also explores the published literature outlining the value of AI and its potential to improve patient care.
Developing an Echocardiography-Based, Automatic Deep Learning Framework for the Differentiation of Increased Left Ventricular Wall Thickness Etiologies
Chao, Chieh‐Ju , Jeong, Jiwoong , Farina, Juan M. , Seri, Amith Reddy , Barry, Timothy , Newman, Hana , Campany, Megan , Abdou, Merna , O’Shea, Michael , Smith, Sean D. , Abraham, Bishoy, Hosseini, Seyedeh Maryam , Wang, Yuxiang , Lester, Steven J., Alsidawi, Said , Wilansky, Susan , Steidley, Eric, Rosenthal, Julie , Appleton, Christopher P., Shen, Win‐Kuang , Grogan, Martha , Kane, Garvan C. , Oh, Jae K. , Patel, Bhavik N. , Arsanjani, Reza , Banerjee, Imon , O’Shea, Michael , Chao, Chieh-Ju , Jeong, Jiwoong Jason, Farina, Juan M , Seri, Amith R, Barry, Timothy , O'Shea, Michael, Smith, Sean , Hosseini, Seyedeh Maryam , Lester, Steven, Alsidawi, Said , Arsanjani, Reza , Banerjee, Imon , Li, James , O’Shea, Michael, Abraham, Bishoy

Mayo Clinic

Journal of Imaging | February 20, 2023 | Volume: 9 | Issue: 2 | Pages: 48

10.3390/jimaging9020048 | PMID 36826967 Get It

Aims:Increased left ventricular (LV) wall thickness is frequently encountered in transthoracic echocardiography (TTE). While accurate and early diagnosis is clinically important, given the differences in available therapeutic options and prognosis, an extensive workup is often required to establish the diagnosis. We propose the first echo-based, automated deep learning model with a fusion architecture to facilitate the evaluation and diagnosis of increased left ventricular (LV) wall thickness. Methods and Results: Patients with an established diagnosis of increased LV wall thickness (hypertrophic cardiomyopathy (HCM), cardiac amyloidosis (CA), and hypertensive heart disease (HTN)/others) between 1/2015 and 11/2019 at Mayo Clinic Arizona were identified. The cohort was divided into 80%/10%/10% for training, validation, and testing sets, respectively. Six baseline TTE views were used to optimize a pre-trained InceptionResnetV2 model. Each model output was used to train a meta-learner under a fusion architecture. Model performance was assessed by multiclass area under the receiver operating characteristic curve (AUROC). A total of 586 patients were used for the final analysis (194 HCM, 201 CA, and 191 HTN/others). The mean age was 55.0 years, and 57.8% were male. Among the individual view-dependent models, the apical 4-chamber model had the best performance (AUROC: HCM: 0.94, CA: 0.73, and HTN/other: 0.87). The final fusion model outperformed all the view-dependent models (AUROC: HCM: 0.93, CA: 0.90, and HTN/other: 0.92). Conclusion: The echo-based InceptionResnetV2 fusion model can accurately classify the main etiologies of increased LV wall thickness and can facilitate the process of diagnosis and workup.
IgA vasculitis nephritis (Schönlein-Henoch purpura with nephritis) following COVID-19 vaccination
Mahmoodnia, Leila , Savadjani, Shahin Asgari , Mostafavi, Leila , Korani, Setayesh Sotoudehnia , Chafjiri, Fatemeh Mohammad Alizadeh , Moghadam, Mahshid Sadat Chenarani , Jahantigh, Hamid Reza , Neshat, Sina , Shirbacheh, Ali , Baharani, Jyoti , Masomi, Rohollah , Hotkani, Zahra Golestani , Sotoudehnia, Setayesh

Mayo Clinic

Journal of Nephropathology | February 15, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.34172/jnp.2023.21447 Get It

IgA vasculitis nephritis (Schönlein-Henoch purpura nephritis) is an autoimmune circumstance characterized by palpable purpura involving the lower limbs, arthralgia, abdominal pain and kidney involvement. It is possible that a cytokine storm following coronavirus disease 2019 (COVID-19) could lead to an immunological dysregulation responsible for IgA vasculitis nephritis in these cases. Reactivation or first onset of IgA vasculitis nephritis is uncommon; however, there have been increasing reports of this disease, as a complication of COVID-19 vaccination. It is possible that COVID-19 mRNA vaccination may trigger several auto-inflammatory and autoimmune cascades. Previous research has shown that Toll-like receptors play a role in the development of IgA vasculitis nephritis. Following injection of a COVID-19 mRNA vaccine, the uptake of double-stranded RNA by-products will trigger Toll-like receptors, leading to a series of intracellular cascades starting an innate immunity-driven process of cell-mediated and humoral- mediated immunity.
Antibody-Based Therapeutics for the Treatment of Renal Cell Carcinoma: Challenges and Opportunities
Mahmoud, Ahmed , Nabavizadeh, Reza , Pessoa, Rodrigo Rodrigues , Garg, I. D. , Orme, Jacob J. , Costello, Brian A. , Cheville, John C. , Mahmoud, Ahmed M , Rodrigues Pessoa, Rodrigo, Garg, Ishita, Lucien, Fabrice , Lucien, Fabrice

Mayo Clinic

The Oncologist | February 6, 2023 | Volume: 28 | Issue: 4 | Pages: 297-308

10.1093/oncolo/oyac263 | PMID 36745503 Get It

AbstractRenal cell carcinoma (RCC) is among the top 10 most common cancers in both men and women with an estimated 75 000 cases each year in the US. Over the last decade, the therapeutic landscape for patients with metastatic RCC has significantly evolved, with immunotherapy emerging as the new front-line therapy. Despite significant improvement in toxicity profile and survival outcomes, key concerns such as patient selection, treatment sequencing, and intrinsic and acquired resistance remain unresolved. Emerging options such as antibody-based therapeutics (eg, anti-CD70, anti-CA9, and anti-ENPP3) are being explored in clinical trials for patients with cancer resistant or refractory to current immunotherapies. Despite positive results for hematological cancers, breast cancer, and more recently bladder cancer, most antibody-based therapies failed to improve the outcomes in patients with advanced RCC. This underscores the need to understand the underlying causes of failed responses to this treatment class, which will ultimately support the rational design of more effective and tolerable treatments. In this review, we summarize the evolving landscape of RCC therapeutics and describe recent clinical trials with emerging antibody-based therapeutics. We also describe the challenges that need to be overcome for the successful creation of therapeutic antibodies for treating RCC.
Risk of Sudden Infant Death Syndrome Among Siblings of Children Who Died of Sudden Infant Death Syndrome in Denmark
Glinge, Charlotte , Rossetti, Sára , Oestergaard, L , Stampe, Niels Kjær , Skals, Regitze Gyldenholm , Lodder, Elisabeth M. , Gislason, Gunnar , Behr, Elijah R. , Jabbari, Reza , Tfelt‐Hansen, Jacob , Behr, Elijah Raphael , Tfelt-Hansen, Jacob , Lynge, Thomas Hadberg , Winkel, Bo Gregers , Bezzina, Connie R. , Banner, Jytte , Torp-Pedersen, Christian Tobias

Mayo Clinic

JAMA Network Open | January 25, 2023 | Volume: 6 | Issue: 1 | Pages: e2252724

10.1001/jamanetworkopen.2022.52724 | PMID 36696110 Get It

Importance Sudden infant death syndrome (SIDS) remains a leading cause of death during the first year of life. The etiology of SIDS is complex and remains largely unknown. Objective To evaluate whether siblings of children who died of SIDS have a higher risk of SIDS compared with the general pediatric population. Design, Setting, and Participants This register-based cohort study used Danish nationwide registers. Participants were all infants (&amp;lt;1 year) in Denmark between January 1, 1978, and December 31, 2016, including siblings of children who died of SIDS. Siblings were followed up from the index cases’ date of SIDS, date of birth, or immigration, whichever came first, and until age 1 year, emigration, developing SIDS, death, or study end. The median (IQR) follow-up was 1 (1-1) year. Data analysis was conducted from January 2017 to October 2022. Main Outcomes and Measures Standardized incidence ratios (SIRs) of SIDS were calculated with Poisson regression models relative to the general population. Results In a population of 2 666 834 consecutive births (1 395 199 [52%] male), 1540 infants died of SIDS (median [IQR] age at SIDS, 3 [2-4] months) during a 39-year study period. A total of 2384 younger siblings (cases) to index cases (first sibling with SIDS) were identified. A higher rate of SIDS was observed among siblings compared with the general population, with SIRs of 4.27 (95% CI, 2.13-8.53) after adjustment for sex, age, and calendar year and of 3.50 (95% CI, 1.75-7.01) after further adjustment for mother’s age (&amp;lt;29 years vs ≥29 years) and education (high school vs after high school). Conclusions and Relevance In this nationwide study, having a sibling who died of SIDS was associated with a 4-fold higher risk of SIDS compared with the general population. Shared genetic and/or environmental factors may contribute to the observed clustering of SIDS. The family history of SIDS should be considered when assessing SIDS risk in clinical settings. A multidisciplinary genetic evaluation of families with SIDS could provide additional evidence.